Effect of cancer stage on health-related quality of life of patients with epithelial ovarian cancer

References

• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. 1993. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85:365–376.
   PubMed Web of Science ®Google Scholar
• Aoki D, Chiyoda T. 2018. PARP inhibitors and quality of life in ovarian cancer. Lancet Oncology 19:1012–1014.
   PubMed Web of Science ®Google Scholar
• Bookman MA, Brady MF, Mcguire WP, Harper PG, Alberts DS, Friedlander M, et al. 2009. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology 27:1419–1425.
   PubMed Web of Science ®Google Scholar
• Charoenkwan, K. 2018. Chiang Mai University Ovarian Cancer Quality of Life questionnaire [online]. Chiang Mai (Thailand): Chiang Mai University; Available from: http://www.wongpakaran.com/index.php?lay=show&ac=article&Id=2147598858 [cited 30 September 2020].
   Google Scholar
• Fader AN, Rose PG. 2007. Role of surgery in ovarian carcinoma. Journal of Clinical Oncology 25:2873–2883.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. 2001. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels (Belgium): European Organisation for Research and Treatment of Cancer.
   Google Scholar
• Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, et al. 2018. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncology 19:1126–1134.
   PubMed Web of Science ®Google Scholar
• GLOBOCAN. 2018. Global cancer observatory. Lyon (France): International Agency for Research on Cancer.
   Google Scholar
• Hipkins J, Whitworth M, Tarrier N, Jayson G. 2004. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. British Journal of Health Psychology 9:569–581.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, Group EGW. 2013. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24:vi24–vi32.
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, De Geest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, et al. 2012. Social influences on clinical outcomes of patients with ovarian cancer. Journal of Clinical Oncology 30:2885–2890.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Mazumder K, Ghoshal S. 2018. Impact of different sociodemographic factors on mental health status of female cancer patients receiving chemotherapy for recurrent disease. Indian Journal of Palliative Care 24:426–430.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. 2020. NCCN clinical practice guidelines in oncology. Ovarian cancer version 1.2020. Plymouth (PA): NCCN.
   Google Scholar
• Nho JH, Reul Kim S, Nam JH. 2017. Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy. European Journal of Oncology Nursing 30:8–14.
   PubMed Web of Science ®Google Scholar
• Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, et al. 2018. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3. The Lancet Oncology 19:1117–1125.
   PubMed Web of Science ®Google Scholar
• Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Sirachainan E, Ratanatharathorn V. 2006. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 15:167–172.
   PubMed Web of Science ®Google Scholar
• Srisuttayasathien M, Khemapech N. 2013. Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment. Asian Pacific Journal of Cancer Prevention 14:7669–7674.
   PubMedGoogle Scholar
• Torre LA, Trabert B, Desantis CE, Miller KD, Samimi G, Runowicz CD, et al. 2018. Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68:284–296.
   PubMed Web of Science ®Google Scholar
• Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. 2018. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology 19:1680–1687.
   PubMed Web of Science ®Google Scholar
• Von Gruenigen VE, Huang HQ, Cella D, Zevon M, Lachance JA, Walker JL, et al. 2018. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology 150:119–126.
   PubMed Web of Science ®Google Scholar
• Wen Q, Shao Z, Zhang P, Zhu T, Li D, Wang S. 2017. Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy. European Journal of Obstetrics, Gynecology, and Reproductive Biology 216:85–91.
   PubMed Web of Science ®Google Scholar
• Wilailak S, Lertkhachonsuk AA, Lohacharoenvanich N, Luengsukcharoen SC, Jirajaras M, Likitanasombat P, Sirilerttrakul S. 2011. Quality of life in gynecologic cancer survivors compared to healthy check-up women. Journal of Gynecologic Oncology 22:103–109.
   PubMed Web of Science ®Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. 2007. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 25:3621–3627.
   PubMed Web of Science ®Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. 2008. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 26:83–89.
   PubMed Web of Science ®Google Scholar